Loading clinical trials...
Loading clinical trials...
An Open-Label Phase 1 Safety and Dose Finding Study of Orally Administered GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Conditions
Interventions
GLIX1
Locations
3
United States
Moffitt Cancer Center
Tampa, Florida, United States
Northwestern Medicine
Chicago, Illinois, United States
NYU Langone Health
New York, New York, United States
Start Date
March 1, 2026
Primary Completion Date
June 1, 2027
Completion Date
December 1, 2027
Last Updated
March 20, 2026
NCT07539441
NCT03206060
NCT04065776
NCT03050268
NCT05636618
NCT07243470
Lead Sponsor
Tetragon Biosciences Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions